Global law firm Clifford Chance has advised dsm-firmenich, innovators in nutrition, health, and beauty, on the sale of its MEG-3® fish oil business to KD Pharma Group SA, a contract development and manufacturing organization (CDMO) active in pharmaceutical and nutritional lipids. As part of the transaction, dsm-firmenich will obtain a minority stake of 29% in KD Pharma Group’s parent company O³ Holding GmbH.
This transaction is expected to be completed towards the end of 2024, and is subject to customary regulatory approvals.
The Clifford Chance core team was led by Gregory Crookes and further consisted of Pieter Leefers, Robin Traas, Maria Boerman, Stijn Theunissen, Michiel Sunderman, Alec Sanderson, Jurre Jurriens and Marc Besen. The wider cross-border team consisted of Boudewijn Vermeer, Jelle Hofland, Samuel van Eijnatten (Global Financial Markets), Pascal Borsjé (Tax), Floris van de Bult, Astrid van Ommeren, Merle van den Berg, Iga Mamczarz (Employment), Wijnanda Rutten (Pensions), Andrei Mikes, Tamlin Higgins, Laura Bredschneijder (Tech//Digital), Serkan Özel (Notary) and Fiorri Michael (Antitrust) in Amsterdam, Simon Schmid, Peter Dieners, Gunnar Sachs, Yannick Niedergethmann, Marlene Kießling, Tobias Jenne (Corporate), Arne Gayk (Antitrust) and Stefan Lohn (Litigation) in Düsseldorf, Olaf Mertgen and Christian Klein (Tax) in Frankfurt, Justin Kottin (Corporate) in Paris, Peter Mucchetti, Brian Concklin and Timothy Lyons (Antitrust) in Washington and Paul Koppel, David Walsh (ERISA) and Kevin Colan and Milica Pavlovic (Tax) in New York.
